至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Diagnostic Efficiency of Three Fully Automated Serology Assays and Their Correlation with a Novel Surrogate Virus Neutralization Test in Symptomatic and Asymptomatic SARS-COV-2 Individuals

Microorganisms. 2021-01; 
Salma Younes, Hadeel Al-Jighefee, Farah Shurrab, Duaa W Al-Sadeq, Nadin Younes, Soha R Dargham, Nader Al-Dewik, Hamda Qotba, Mohamed Syed, Ahmed Alnuaimi, Hadi M Yassine, Patrick Tang, Laith J Abu-Raddad, Gheyath K Nasrallah
Products/Services Used Details Operation
Catalog Antibody This assay was developed by GenScript® Biotech and is now available commercially as 96-well microplates for large serological screening for neutralizing antibodies targeting the RBD domain of the S1 subunit Get A Quote

摘要

To support the deployment of serology assays for population screening during the COVID-19 pandemic, we compared the performance of three fully automated SARS-CoV-2 IgG assays: Mindray CL-900i (target: spike [S] and nucleocapsid [N]), BioMérieux VIDAS3 (target: receptor-binding domain [RBD]) and Diasorin LIAISONXL (target: S1 and S2 subunits). A total of 111 SARS-CoV-2 RT-PCR- positive samples collected at ≥ 21 days post symptom onset, and 127 pre-pandemic control samples were included. Diagnostic performance was assessed in correlation to RT-PCR and a surrogate virus-neutralizing test (sVNT). Moreover, cross-reactivity with other viral antibodies was investigated. Compared to RT-PCR, LIAISONXL showed the hig... More

关键词

COVID-19, SARS-CoV-2, neutralizing antibodies, sensitivity, serology, specificity, surrogate virus neutralization test (sVNT)